Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

Archives of Internal Medicine

Volumn 165, Issue 5, 2005, Pages 490-496

  Aw, Tai Juan ^a   Haas, Steven Joseph ^b   Liew, Danny ^b   Krum, Henry ^a,b  

^a NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HUMAN; HYPERTENSION; META ANALYSIS; OSTEOARTHRITIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CONFIDENCE INTERVALS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; RISK;

EID: 14844337012     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.5.IOI50013     Document Type: Article

References (47)

1. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477-484.
2. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis .N Engl J Med. 2000;343:1520-1528.
3. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
4. Kerr SJ, Mant A, Horn FE, McGeechan K, Sayer GP. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust. 2003;179:403-407.
5. Pharmaceutical Benefits Schedule Item Statistics (last updated November 25, 2003) Health Insurance Commission (HIC). Available at: http://www.hic.gov.au /statistics/dyn_pbs/forms/pbs_tab1.shtml. Accessed June 2004.
6. Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut. 2003;52:820-826.
7. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280-2288.
8. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients - SUCCESS VI. Am J Ther. 2001;8:85-95.
9. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-963.
10. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension. 2002;39:929-934.
11. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? a meta-analysis. Ann Intern Med. 1994;121:289-300.
12. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40:1347-1365.
13. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002;89:425-430.
14. Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract. 2002;3:10.
15. Ehrich EW, Schnitzer TJ, McIlwain H, et al; Rofecoxib Osteoarthritis Pilot Study Group. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol. 1999;26:2438-2447.
16. Geba GP. Hypertension and related adverse events among diabetic patients treated with rofecoxib or naproxen in the population of an osteroarthritis trial: ADVANTAGE. Paper present at: American College of Rheumatology Annual Scientific Meeting; October 24-28, 2003; Orlando, Fla. Abstract 1577.
17. Sowers J, Vaningen H, White WB, et al. Rofecoxib, but not celecoxib, at doses providing equal OA efficacy, increases mean 24-hr systolic blood pressure in treated hypertensive patients with osteoarthritis and type 2 diabetes mellitus. Paper presented at: Annual European Congress of Rheumatology, European League Against Rheumatism; June 20, 2003; Lisbon, Portugal. Abstract FRI0279.
18. Whelton A. Celecoxib does not increase the risk of cardiac failure, edema, or hypertension compared to NSAIDs: results from SUCCESS I, a double blind, randomized trial in 13,274 OA patients. Paper presented at: Annual European Congress of Rheumatology, European League Against Rheumatism; June 16, 2001; Prague, Czech Republic. Abstract SAT0094.
19. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265: 3255-3264.
20. Staessen JA, Fagard R, Thijs L, et al; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
21. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778-799.
22. Harley C, Wagner S. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. Clin Ther. 2003;25:139-149.
23. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med. 1991;90:42S-47S.
24. Cannon GW, Caldwell JR, Holt P, et al; Rofecoxib Phase III Protocol 035 Study Group. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum. 2000;43:978-987.
25. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999;354:2106-2111.
26. Hunt RH, Harper S, Callegari P, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther. 2003;17:201-210.
27. Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin. 2002;18:49-58.
28. Lisse JR, Perlman M, Johansson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med. 2003;139:539-546.
29. Matsumoto AK, Melian A, Mandel DR, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002;29:1623-1630.
30. Schnitzer TJ, Truitt K, Fleischmann R, et al; Phase II Rofecoxib Rheumatoid Arthritis Study Group. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin Ther. 1999;21:1688-1702.
31. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921-1928.
32. Geba GP. Comparative blood pressure effects of rofecoxib, celecoxib, and placebo in patients with osteoarthritis (OA): a randomized controlled trial. Paper presented at: Annual European Congress of Rheumatology, European League Against Rheumatism; June 16, 2001; Prague, Czech Republic. Abstract No. SAT0095.
33. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement: Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896-1900.
34. NDA 20-998/S-009 (Celecoxib): results from CLASS Medical officer review. February 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing /3677b1_03_med.pdf. Accessed June 2004.
35. NDA 21-042 and 21-052 (rofecoxib): results from VIGOR FDA Advisory Committee Background Information. February 2001. Available at: http://www.fda.gov /ohrms/dockets/ac/01/briefing/3677b2_01_merck.pdf. Accessed June 2004.
36. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd ed. London, England: BMJ Publishing Group; 2001:285-312.
37. Sterne JAC, Bradburn MJ, Egger M. Meta-analysis in Stata. In: Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd ed. London, England: BMJ Publishing Group; 2001:347-69.
38. Landsberg PG, Pillans PI, Radford JM. Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital. Intern Med J. 2003;33:225-228.
39. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens. 2000;14:83-90.
40. Leonetti G, Cuspidi C, Facchini M, Stramba-Badiale M. Is systolic pressure a better target for antihypertensive treatment than diastolic pressure? J Hypertens Suppl. 2000;18:S13-S20.
41. Morgan TO, Anderson A, Bertram O. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens. 2000;13:1161-1167.
42. Cutts C, LaCaze A, Tett S. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. Br J Clin Pharmacol. 2002;54:522-527.
43. VIOXX (rofecoxib) [package insert]. West Point, Pa: Merck and Co, Inc; 2001.
44. Liew D, Krum H. The role of aldosterone receptor blockade in the management of cardiovascular disease. Curr Opin Investig Drugs. 2002;3:1468-1473.
45. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
46. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
47. Flather MD, Farkouh ME, Pogue JM, Yusuf S. Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials. 1997;18:568-579.